CONNECT WITH US
Tech

Tech

McDonald’s is changing its menu for the Ozempic era

Fast Company logo

Published on

Add as a preferred source on Google
McDonald’s is changing its menu for the Ozempic era

As part of an $8.5 billion overhaul of the restaurants planned over the next decade, the fast food giant is planning to meet customers amid a new era of eating habits. 

According to data from Gallup, around 11% of the US population is currently using a GLP-1 medication for weight loss purposes. Due to the rapid effects of the medication, those using drugs like Ozempic or Mounjaro need to prioritize protein intake to prevent muscle loss—a habit that has since led to a boom in protein-packed products. 

And now, McDonald’s is looking to jump on board with the protein craze, McDonald’s executives announced during the company’s investor day in Chicago on Sept. 23.

The plan announced is set to roll out new menu items across various markets, including new wraps and grilled chicken sandwiches. Additionally, the new menu items may include bowls and egg bites, providing customers with high protein options at various sizes.

“This is an opportunity. We need to keep giving them more reasons to make McDonald’s their first choice,” Skye Anderson, the president of McDonald’s USA, said during the investor day event.

In addition to tapping into a growing customer base looking for protein, McDonald’s is also looking to modernize the restaurants as a whole. For instance, stores are set to be equipped with lockers for delivery orders, improved kitchen layouts, and AI-enabled technology to help improve the restaurant’s productivity. 

Developed with Google, the restaurant’s AI system includes the deployment of the ArchIQ system, which helps track inventory and schedule, as well as take orders in Spanish and English via the drive-thru system.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.